This is the authors' abstract. We don't add key points for this paper.
Three novel 4‐aryl‐2‐(2‐(4‐fluorophenyl)‐2‐oxoethyl)‐6‐phenylpyridazin‐3(2 H )‐one derivatives were synthesized, and their chemical structures were established based on 1 H‐NMR, 13 C‐NMR, ESI‐HRMS, and FT‐IR spectral data. Their in vitro antibacterial activities were evaluated against Staphylococcus aureus [MRSA] (Gram‐positive isolate), Escherichia coli and Salmonella typhimurium (Gram‐negative isolates), and Pseudomonas aeruginosa and Acinetobacter baumannii (Gram‐negative nonfermenter isolates), and the results were compared with the standard drug “Amikacin”. The results showed that one of the compounds has good antibacterial activity against P. aeruginosa (MIC = 11.57 µM) and E. coli (MIC = 23.14 µM). In order to gain molecular insights into the compounds, their reactivity properties were studied using density functional theory (DFT), and molecular docking was carried out for the compounds with E. coli MurB protein receptors (2Q85).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Daoui et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: